Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Alarmfase vier wegens varkensgriep Uitgegeven: 27 april 2009 22:46 Laatst gewijzigd: 27 april 2009 22:46www.nu.nl/algemeen/1955736/alarmfase-... GENEVE - De Wereldgezondheidsorganisatie (WHO) heeft maandagavond tijdens spoedoverleg in Geneve het alarmniveau voor de dodelijke varkensgriep verhoogd van fase drie naar vier. Oorspronkelijk zou de bijeenkomst dinsdag worden gehouden, maar de WHO besloot wegens de situatie in Mexico eerder bijeen te komen. Volgens de VN-organisatie is het risico op een pandemie wezenlijk toegenomen. Hele gemeenschappen kunnen worden geraakt door besmetting van mens op mens. Verspreiding De WHO wil nu de nadruk leggen op het tegengaan van de verspreiding van het nieuwe virus. Landen wordt gevraagd reisadviezen en controles van reizigers te overwegen. Getroffen landen zouden vaccinatiecampagnes moeten overwegen, evenals beperking van de bewegingsvrijheid van personen in besmet gebied.
[modbreak Paul forum@iex.nl : Even de link in 2 stukjes gehakt om de pagina leesbaar te houden.] Dank je wel, service hoor! ******************** @ dirk Link van pag.8 werkt zonder Telegraaf-tussenkomst.www.idemc.org/
Sanofi ready, willing and able — but a vaccine will take time By HOWARD FRANK Pocono Record Writer April 28, 2009 Swiftwater vaccine maker Sanofi Pasteur is ready to help health agencies develop a vaccine to neutralize the swine influenza reported here and in other parts of the world — as soon as they're given the go-ahead. In a written statement, the company said: "In the event that WHO (the World Health Organization) and other health authorities identify the need for a specific swine influenza A/H1N1 vaccine, Sanofi Pasteur is ready to work with health and regulatory authorities to develop a vaccine candidate." But it won't happen fast. "What I can tell you is that under our anticipated manufacturing time cycle, the first doses of any influenza vaccine should become available a few months after delivery of the viral strain, provided that the manufacturers also have received the relevant reagents from a WHO reference center in due time. Of course, we would work closely with health authorities to make every effort to shorten the time for vaccine availability," Ellyn Schindler, a spokesperson for Sanofi Pasteur, said. Until they begin working with the seed virus and are able to characterize its potential yield, it would be speculative to provide any reliable time frame, she added. Sanofi hasn't been asked to work on a vaccine yet, but preparations are being made in case such a request is made. "We have been and continue to be in active in discussions with (U.S.) public health officials on this topic, and the authorities are taking the necessary steps to be able to make such a request if it should prove necessary," Schindler said. It's a rapidly evolving situation and Schindler said it's Sanofi's understanding that the U.S. Centers for Disease Control, the WHO and the European CDC are still working to isolate the genetic characteristics of all the virus strains identified so far. That has to happen before selecting and producing seed that could be used for vaccine production. The ball is in the world health organizations' court. "When they have the necessary information to determine if vaccine production would be beneficial, they know we are standing by and they will contact us. Until then, Sanofi Pasteur, as the world's leading producer of influenza vaccine, is coordinating closely with these agencies and maintaining its capabilities at a high state of readiness, should health authorities request support from influenza vaccine manufacturers," Schindler said.www.poconorecord.com/apps/pbcs.dll/ar... ************** Operationeel deeldraaiboek 2. Incidentele introductie nieuw humaan influenzavirus in Nederlandwww.rivm.nl/cib/binaries/DB%20Intr%20... class=
Top Swine Flu Stocks Swine Flu Stock #3: Crucell Crucell (CRXL) is the 21st-century vaccine technology company, and its business model is to be the "Intel Inside" for many vaccine makers. Crucell owns a traditional vaccine business and is also developing new vaccines for many infectious diseases. Its technology platform -- cell-line manufacturing -- is much more efficient than traditional egg-based vaccine production, and the company has partnered with many of the major players in the vaccine business. www.optionszone.com/trading-ideas/200...
Vical Updates Lead Vaccine Programs At NFID Vaccine Research Conference and Addresses Potential Response to H1N1 Swine Influenza Outbreak On Tuesday April 28, 2009, 6:30 am EDT BALTIMORE, April 28, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (NasdaqGM:VICL - News) today announced that the company's Vice President of Vaccine Research, Larry R. Smith, Ph.D., is presenting updates on the company's pandemic influenza and cytomegalovirus (CMV) vaccine programs at the 12th Annual Conference on Vaccine Research sponsored by the National Foundation for Infectious Diseases (Baltimore, April 27 - 29). "Phase 1 Safety and Immunogenicity Results of Vaxfectin(r)-formulated Plasmid DNA Vaccines Encoding Influenza Virus H5 Hemaggluntinin,'' an oral presentation, summarizes results from the company's successful Phase 1 trial and future goals for its pandemic influenza DNA vaccine program. The double-blind, placebo-controlled, dose-escalation Phase 1 trial was conducted in approximately 100 healthy volunteers age 18 to 45 at three U.S. clinical sites. The trial was designed to assess safety and immunogenicity following vaccination, and to evaluate monovalent and trivalent Vaxfectin(r)-formulated H5N1 pandemic influenza DNA vaccines at various doses. The vaccines were safe and well tolerated in the trial, and induced antibody responses and T-cell responses against a matching strain of influenza virus, and cross-clade antibody responses against different strains. The current public health emergency caused by outbreaks of H1N1 swine influenza highlights the need for a faster method to develop and produce vaccines. Vical's technology could produce a vaccine within six to nine weeks after the H1 hemagglutinin gene is sequenced. If the U.S. government or an international health agency issues a directive and provides the necessary resources, Vical is prepared to respond. In its broader pandemic influenza effort, Vical is currently exploring potential sources of funding for further development. The company's near-term goals are to confirm vaccine safety and immunogenicity in a larger number of subjects, optimize vaccine dose and adjuvant ratio, explore prime-boost regimens with different vaccines, and leverage the Phase 1 proof of concept for its DNA vaccine platform and Vaxfectin(r) adjuvant into additional indications. En aanvullend moeten ze de boer op om dit te financieren. Vical Exploring Funding For Pandemic Flu Effort >VICL Last update: 4/28/2009 6:32:51 AM(MORE TO FOLLOW) Dow Jones Newswires (201-938-5400)April 28, 2009 06:32 ET (10:32 GMT)Copyright © 2009 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. Dirk
Wow, Trudy is boos…. Van nostra (www.ErikErik.com)www.crazymonkeygames.com/jkf6Tr/pande...
Flu Vaccine: Drugmakers Could Be Ready Soon Fears over infectious outbreaks, from SARS to bird flu to the latest swine-borne virus, have boosted investment in vaccines and fostered fresh approaches By John Carey No one knows yet whether the flu outbreak in Mexico and in states like New York and California will turn into a major pandemic or a forgettable blip in the annals of infectious diseases. It's not even clear exactly what to call the virus, since it seems to have acquired genes from both pigs and birds on its evolutionary journey to making people sick. "As far as we know, this never happened before," says Laurie A. Garrett, senior fellow at the Council on Foreign Relations and author of The Coming Plague: Newly Emerging Diseases in a World Out of Balance. Maybe we should call it the swinebird flu. The good news is that the world—especially the vaccine industry—is far better prepared to deal with a threat such as the new influenza virus than it was just a few years ago. Key decisions to rush through a vaccine have yet to be made. But governments around the world could move quickly to tap the industry's capability if the outbreak continues to worsen. One scenario floated by the Centers for Disease Control in Atlanta: The U.S. government could direct a drug company to drop some of its current development projects, create a swine flu vaccine, and start ramping up manufacturing. An action like that would be costly and politically fraught. But the surprising thing is that such a step is even possible. That certainly was not the case during the flu season of 2004-2005. Back then, the pharmaceutical industry couldn't make enough vaccine for regular flu. There were only two companies in the business—Aventis Pasteur (now a unit of Sanofi-Aventis (SNY)) and Chiron (since acquired by Novartis (NVS)). One of Chiron's facilities had to be shut down during that outbreak because of safety concerns. Egg-Cultivated Vaccines Take Time What has occurred in the interim is a vaccine revival fueled by both improved profitability and an increase in government dollars. Three pharmaceutical giants now manufacture flu vaccine: Sanofi-Aventis, Novartis, and GlaxoSmithKline (GSK), along with small players such as MedImmune, a unit of AstraZeneca (AZN). These companies are already gearing up to make the vaccine for next winter's flu season. There's enough capacity among the players to ramp up production of swine flu vaccine—assuming funding is available—and still prepare for the regular flu season. The bad news? The latest threat can't be squelched quickly or completely with a vaccine produced by traditional methods. The manufacturing process takes months because the virus first must be carefully grown in eggs, then harvested to be turned into a vaccine. Yet there's possibly a way around this problem. Over the past few years, several companies have sprung up to develop methods for making vaccines more quickly, such as growing viruses in cells rather than eggs. These processes hold considerable promise, but none has been licensed yet by the Food & Drug Administration. One of the difficult decisions the Obama Administration will face if the epidemic threatens to spin out of control is whether to fast-track approval of one of these next-generation vaccines in order to make it available more quickly. "If this turns out to be a crisis, the government might go to one of the newer technologies that has quicker production," explains John Clerici, chair of the life sciences and public health practice at law firm McKenna Long & Aldridge. The bigger the crisis, the greater the tolerance for regulatory risks.www.businessweek.com/technology/conte...
PlanFirst Webcasts on Pandemic Influenza The scheduled Webcast on State-based public health pandemic planning accomplishments and efforts has been postponed. There will be a Webcast on Wednesday, April 29th at 2 p.m. ET. on the current swine flu situation. Details about the Webcast will be provided as soon as they become available.www.pandemicflu.gov/news/panflu_webin... ************************ These samples, which can then be distributed to companies, must be grown in specially produced chicken eggs in a cumbersome system that experts agree is outdated. New and more efficient technologies based on cell cultures are, however, still a few years away. While the race is on to prepare a pandemic vaccine, health authorities and companies still have to make the tricky decision of when, or indeed whether, to switch capacity from producing seasonal vaccines to making the new shot. "If you go to pandemic flu production, people won't get normal flu shots -- it is a huge consideration," said WHO spokesman Gregory Hartl. At least 20 companies, in addition to Novartis, make flu vaccines, including Sanofi-Aventis, GlaxoSmithKline, Baxter International, Australia's CSL and nasal spray maker MedImmune, now part of AstraZeneca. They are currently geared to producing season flu shots, which vaccine specialists say will not stop the new form of swine flu spreading around the world, although people who have been immunised may end up with milder symptoms. So-called swine flu is a variant of the H1N1 form of the human influenza virus, but tests show the H1N1 component of the current seasonal flu vaccine does not protect against the new strain. A big challenge facing manufacturers will be making sufficient quantities of vaccine from a limited supply of active ingredient, or antigen. One option to extend supply is to use an additive, known as an adjuvant, to increase the body's immune response and reduce the amount of antigen needed in each shot. Several companies are working on this approach. Glaxo, in particular, said it believed its novel adjuvant technology could make a significant contribution to antigen sparing. The British company previously developed a vaccine against the H5N1 strain of bird flu -- originally thought to pose the biggest pandemic threat -- using a special adjuvant that allowed an extremely low dose of active ingredient to be used. Credit Suisse analysts said companies with the know-how to make pandemic flu vaccines stood to benefit from additional sales, adding there could also be an increase in seasonal flu vaccine demand as disease awareness increases.uk.reuters.com/article/swineFluH1N1/i...
As an influenza vaccine manufacturer Crucell is aware of the current situation in Mexico and other affected countries. Crucell is in active dialogue with the relevant governmental authorities and non governmental organizations (NGOs), while suitable actions to the situation are being decided. As an active member of the International Vaccine Supply Task Force and the International Federation of Pharmaceutical Manufacturers and Associations, Crucell will work with other industry members, health authorities and NGOs to respond as rapidly as possible and in accordance with key recommendations made by the World Health Organization (WHO). In response to a request from the Pan American Health Organization, Crucell is looking to mobilize remaining (limited) stocks of its 2008/2009 seasonal vaccine Inflexal® V for supply to Mexico. Although at this stage it is not clear if existing seasonal flu vaccines induce protective immunity to the currently circulating H1N1 swine flu virus strain. The situation appears to be evolving rapidly, therefore Crucell's response will be tailored to support the public health needs, once more information becomes available, and as directed by organizations such as the WHO. Crucell has an active influenza R&D program to improve the prevention and treatment of seasonal and pandemic influenza: Crucell is testing new adjuvants and new routes of administration in humans for virosome-based pandemic influenza vaccines in the EU (Panfluvac program). Sanofi Pasteur is using Crucell's PER.C6® technology to produce the next generation influenza vaccines. Crucell has discovered human monoclonal antibodies broadly protecting against H1 strains to which family the current swine flu virus belongs. The most potent and broadly reactive of these antibodies is currently being prepared for clinical testing. www.crucell.com/feature_Swineflu_stat...
ved schreef:
As an influenza vaccine manufacturer Crucell is aware of the current situation in Mexico and other affected countries. Crucell is in active dialogue with the relevant governmental authorities and non governmental organizations (NGOs), while suitable actions to the situation are being decided. As an active member of the International Vaccine Supply Task Force and the International Federation of Pharmaceutical Manufacturers and Associations, Crucell will work with other industry members, health authorities and NGOs to respond as rapidly as possible and in accordance with key recommendations made by the World Health Organization (WHO). In response to a request from the Pan American Health Organization, Crucell is looking to mobilize remaining (limited) stocks of its 2008/2009 seasonal vaccine Inflexal® V for supply to Mexico. Although at this stage it is not clear if existing seasonal flu vaccines induce protective immunity to the currently circulating H1N1 swine flu virus strain. The situation appears to be evolving rapidly, therefore Crucell's response will be tailored to support the public health needs, once more information becomes available, and as directed by organizations such as the WHO.
Crucell has an active influenza R&D program to improve the prevention and treatment of seasonal and pandemic influenza:
Crucell is testing new adjuvants and new routes of administration in humans for virosome-based pandemic influenza vaccines in the EU (Panfluvac program).
Sanofi Pasteur is using Crucell's PER.C6® technology to produce the next generation influenza vaccines.
Crucell has discovered human monoclonal antibodies broadly protecting against H1 strains to which family the current swine flu virus belongs. The most potent and broadly reactive of these antibodies is currently being prepared for clinical testing.
www.crucell.com/feature_Swineflu_stat... Dat bedoel ik, kusje erbij! ***************************** Baxter & Gilead Make Money From Swine Flu Lee Brodie CNBC Tuesday, April 28, 2009 Stocks traded modestly lower by mid-day Monday. New details about the swine flu gave health care and biotech names a boost but dragged down the airlines, hotels and other travel & leisure names. Shares of Baxter, GlaxoSmithKline, Crucell and Gilead all made gains on the potential that they could benefit from vaccines and treatments. Both Crucell and Gilead are names that I’m watching explains Jon Najarian, because they both have a great deal of vaccine exposure. But they’re also trading down to their session lows, which suggests the panic may be abating. Of course, there will be companies that make money from swine flu — it seems to me GlaxoSmithKline and Baxter are probably good plays on that, Najarian adds.www.cnbc.com/id/30417735
Site Crucell d.d. 28 april 2009 As an influenza vaccine manufacturer Crucell is aware of the current situation in Mexico and other affected countries. Crucell is in active dialogue with the relevant governmental authorities and non governmental organizations (NGOs), while suitable actions to the situation are being decided. As an active member of the International Vaccine Supply Task Force and the International Federation of Pharmaceutical Manufacturers and Associations, Crucell will work with other industry members, health authorities and NGOs to respond as rapidly as possible and in accordance with key recommendations made by the World Health Organization (WHO). In response to a request from the Pan American Health Organization, Crucell is looking to mobilize remaining (limited) stocks of its 2008/2009 seasonal vaccine Inflexal® V for supply to Mexico. Although at this stage it is not clear if existing seasonal flu vaccines induce protective immunity to the currently circulating H1N1 swine flu virus strain. The situation appears to be evolving rapidly, therefore Crucell's response will be tailored to support the public health needs, once more information becomes available, and as directed by organizations such as the WHO. Crucell has an active influenza R&D program to improve the prevention and treatment of seasonal and pandemic influenza: Crucell is testing new adjuvants and new routes of administration in humans for virosome-based pandemic influenza vaccines in the EU (Panfluvac program). Sanofi Pasteur is using Crucell's PER.C6® technology to produce the next generation influenza vaccines. Crucell has discovered human monoclonal antibodies broadly protecting against H1 strains to which family the current swine flu virus belongs. The most potent and broadly reactive of these antibodies is currently being prepared for clinical testing.
De radio was kapot in Leiden . Is inmiddels gerepareerd, blijkbaar.
wilb52 schreef:
De radio was kapot in Leiden .
Is inmiddels gerepareerd, blijkbaar.
Maar de mail en phone niet......
B_B schreef:
Yet there's possibly a way around this problem. Over the past few years, several companies have sprung up to develop methods for making vaccines more quickly, such as growing viruses in cells rather than eggs. These processes hold considerable promise, but none has been licensed yet by the Food & Drug Administration. One of the difficult decisions the Obama Administration will face if the epidemic threatens to spin out of control is whether to fast-track approval of one of these next-generation vaccines in order to make it available more quickly. "If this turns out to be a crisis, the government might go to one of the newer technologies that has quicker production," explains John Clerici, chair of the life sciences and public health practice at law firm McKenna Long & Aldridge. The bigger the crisis, the greater the tolerance for regulatory risks.
www.businessweek.com/technology/conte... Zie hier enkele versoepelingen. WASHINGTON (AP) -- The Food and Drug Administration has issued emergency guidance that allows certain antiviral drugs to be used in a broader range of the population in case mass dosing is needed to deal with a widespread swine flu outbreak. The agency originally approved the use of the antiviral drug Tamiflu for the prevention and treatment of influenza in adults and children age 1 and older. Another antiviral drug, Relenza, was originally approved to treat people 7 and older and to help prevent flu in those 5 and older. Late Monday, the FDA said it issued emergency guidance to allow Tamiflu to treat and prevent flu in children under 1 and to provide doses other than originally approved in children over 1. The drugs may be distributed to larger segments of the population without complying with the approved label requirements, the FDA said. The agency also authorized a swine flu diagnostic test for testing samples from people with certain flu infections -- those whose virus subtypes cannot be identified by currently available tests.finance.yahoo.com/news/FDA-approves-e...
Farmaceuten aan de slag met varkensgriepvaccin Uitgegeven: 28 april 2009 14:58 Laatst gewijzigd: 28 april 2009 14:58 AMSTERDAM - Farmaceuten hebben de eerste stappen genomen in de ontwikkeling van een vaccin tegen varkensgriep. Het Zwitserse Novartis heeft inmiddels de genetische code van de nieuwe virusvariant H1N1 ontvangen. Er zijn wereldwijd minstens 20 bedrijven die griepvaccins maken. Volgens persbureau AP houden naast Novartis onder meer Sanofi-Aventis, GlaxoSmithKline en Baxter International zich hiermee bezig. In Nederland ontwikkelt het biotechnologiebedrijf Crucell antilichamen tegen verschillende vormen van griep. Het Leidse concern boekte maandag een koersstijging van 8 procent op speculaties dat het een oplossing voor de varkensgriep kan bieden met zijn zogenoemde CR6261-antilichaam. Volgens een analist van RBS is die reactie echter ‘voorbarig’. Maanden Volgens de Wereldgezondheidsorganisatie WHO zal het echter nog vijf tot zes maanden in beslag nemen tot een eventueel vaccin tegen de varkensgriep commercieel beschikbaar is. De farmaciesector is momenteel slechts toegerust voor de productie van de conventionele griepprik. Volgens specialisten zal dit niet afdoende zijn om de nieuwe variant een halt toe te roepen. Gevaccineerde mensen zullen waarschijnlijk hooguit mildere symtomen van de varkensgriep te verduren krijgen.www.nuzakelijk.nl/20090428/algemeen/f... Pakket met kweekjes varkensgriepvirus ontploft In een Zwitserse trein is maandagavond een pakket met kweekjes van het varkensgriepvirus H1N1 ontploft. Het ging niet om de mutatie die in Mexico mogelijk 150 levens heeft geëist. Volgens de autoriteiten is er geen besmettingsgevaar door de explosie. Het materiaal was bestemd voor een onderzoekscentrum voor griep in Genève. Door de explosie raakten twee mensen lichtgewond, aldus de Zwitserse politie. Een medewerker van het instituut in Genève had in Zürich acht flessen met het virus opgehaald. Het materiaal werd in ijs met kooldioxide koel gehouden. Vermoedelijk was de explosie het gevolg van overdruk in het pakket.www.depers.nl/buitenland/303395/Pakke...
28 april 2009novum Negatief reisadvies voor Mexico (Novum) - Het ministerie van Buitenlandse Zaken raadt af om naar Mexico te reizen als dat niet noodzakelijk is. Reden is de uitbraak van varkensgriep, laat het departement dinsdag weten. Alle zogeheten 'niet-essentiële' reizen worden ontraden. Wanneer het ministerie een dergelijk advies uitgeeft, is sprake van een 'verhoogd veiligheidsrisico' in het hele land. De Wereldgezondheidsorganisatie WHO verhoogde maandag het alarmniveau als gevolg van de uitbraak. Er is sprake van een verhoogde kans op een wereldepidemie, nu er mens-op-mensbesmetting is geconstateerd. "Ik raad iedereen aan om onze reisadviezen goed in de gaten te houden en de informatie op de site van het Rijksinstituut voor Volksgezondheid en Milieu en de WHO te volgen", aldus minister van Buitenlandse Zaken Maxime Verhagen (CDA) in een toelichting. Het blijft echter de verantwoordelijkheid van de reiziger zelf en de touroperator om een reis naar Mexico al dan niet te laten doorgaan. Dirkwww.trouw.nl/nieuws/nederland/article...
Europe braced for spread of flu More cases of swine flu in humans are likely to emerge across Europe in the coming days, EU Health Commissioner Androulla Vassiliou has warned. In addition to Spain and the UK, Ms Vassiliou said suspected cases were also being investigated in the Republic of Ireland, Denmark, Germany, Italy, Sweden, Greece and the Czech Republic.news.bbc.co.uk/1/hi/world/americas/80... ******************* US Swine Flu Cases Rise To 45 In his first public remarks on the situation, President Obama urged Americans on Monday to remain calm as the number of US cases of swine flu more than doubled and the World Health Organization raised its pandemic threat level. As the confirmed number of US cases reached 45 yesterday, ABC World News reported that the President "urged calm." The President was shown saying: "This is obviously a cause for concern and requires a heightened state of alert. But it's not a cause for alarm." Obama, McClatchy reports, "worked...to assure the nation, and perhaps the world, that an outbreak of swine flu is a cause for concern but not alarm." And as "fears of a growing deadly global swine flu epidemic appear to be growing by the hour," CNN's The Situation Room noted that "from the President on down, the Obama Administration is moving quickly to calm Americans about a possible pandemic."www.usnews.com/usnews/politics/bullet... *************** CDC-teller staat nog op 40.www.cdc.gov/swineflu/
Dirk R. Wijnen schreef:
28 april 2009novum
Negatief reisadvies voor Mexico
(Novum) - Het ministerie van Buitenlandse Zaken raadt af om naar Mexico te reizen als dat niet noodzakelijk is. Reden is de uitbraak van varkensgriep, laat het departement dinsdag weten.
Alle zogeheten 'niet-essentiële' reizen worden ontraden. Wanneer het ministerie een dergelijk advies uitgeeft, is sprake van een 'verhoogd veiligheidsrisico' in het hele land.
De Wereldgezondheidsorganisatie WHO verhoogde maandag het alarmniveau als gevolg van de uitbraak. Er is sprake van een verhoogde kans op een wereldepidemie, nu er mens-op-mensbesmetting is geconstateerd.
"Ik raad iedereen aan om onze reisadviezen goed in de gaten te houden en de informatie op de site van het Rijksinstituut voor Volksgezondheid en Milieu en de WHO te volgen", aldus minister van Buitenlandse Zaken Maxime Verhagen (CDA) in een toelichting.
Het blijft echter de verantwoordelijkheid van de reiziger zelf en de touroperator om een reis naar Mexico al dan niet te laten doorgaan.
Ik hoop niet dat onderstaande een reden is alsnog te gaan..... ROTTERDAM - Reizigers krijgen hun geld niet terug, als ze om de Mexicaanse griep hun reis naar een gebied waar de ziekte heerst, annuleren. Het Calamiteitenfonds keert alleen uit als mensen hun vakantie afzeggen bij natuurrampen en molest. www.telegraaf.nl/reiskrant/3801827/ __Geen_geld_terug_bij_annulering_reis_om_Mexicaanse_griep__.html?p=20,1
Is er al een Swineflu gekonstateerd in het Rhein Gebiet, wo der Wein gemacht wird=== Nein= Gut Geh ich hin.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
913,39
+0,30%
EUR/USD
1,0885
+0,01%
FTSE 100
8.445,80
+0,21%
Germany40^
18.875,90
+0,03%
Gold spot
2.388,02
+0,06%
NY-Nasdaq Composite
16.742,39
+1,40%
Stijgers
Dalers